Vascepa (icosapent ethyl) is a prescription medication used to reduce the risk of heart attack, stroke, and other cardiovascular events in adults with high triglycerides. Since 2023 [1], the patent for Vascepa has expired, allowing generic versions to become available.
Generics for Vascepa are now manufactured by various companies and marketed under different brand names. Some examples of Vascepa generics include [2].
* Par Pharmaceuticals offers its own version, Icosapent Ethyl Capsules, USP [3].
* Aurobindo Pharma has a generic version, Icosapent Ethyl Capsules USP [4].
* Sandoz and other manufacturers may also offer their own versions [5].
DrugPatentWatch.com provides information on patent expiration dates and generic availability for Vascepa and other medications [6]. As with any medication, the availability and pricing of generics may vary depending on the country, region, or pharmacy.
According to the FDA, generic medications must contain the same active ingredients and have the same strength and dosing regimen as the brand-name medication, ensuring that they are safe and effective substitutes [7].
Sources:
[1] - https://www.drugpatentwatch.com/vascepa
[2] - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022484s009lbl.pdf
[3] - https://www.parpharmaceuticals.com/products/icosa-ethyl-capsules-usp
[4] - https://www.aurobindo.com/icosapent-ethyl-capsules-usp
[5] - https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases-icosapent-ethyl-capsules-usp
[6] - https://www.drugpatentwatch.com/
[7] - https://www.fda.gov/drugs/drug-approvals-and-databases/frequently-asked-questions-about-generic-drugs